Diadema Partners’s Monopar Therapeutics MNPR Stock Holding History

Diadema Partners’s Portfolio MNPR Stock Details MNPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$151K	Hold	1,630	–	–	0.02%	132
2026 Q1	$89.3K	Buy	+1,630	New	+$98.5K	0.02%	131

Other funds holding MNPR

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Diadema Partners's MNPR Position: Q2 2026 in Review

Diadema Partners held its Monopar Therapeutics (MNPR) position steady in Q2 2026 at 1,630 shares worth $151K. The position accounts for 0.02% of the portfolio, ranked #132.

Diadema Partners first reported a position in MNPR in Q1 2026 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

Diadema Partners held 1,630 shares of Monopar Therapeutics worth $151K as of Q2 2026.
Diadema Partners left its Monopar Therapeutics share count unchanged in Q2 2026.
Monopar Therapeutics made up 0.02% of Diadema Partners's portfolio in Q2 2026, its #132 holding.
Diadema Partners first reported a position in Monopar Therapeutics in Q1 2026 and has held it in 2 quarters since.
96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.